Treatment outcomes of benign paroxysmal positional vertigo.
OBJECTIVE
The purpose of this study was to examine the efficacy of the particle repositioning manoeuvre (PRM) in the treatment of benign paroxysmal positional vertigo (BPPV).


METHODS
A randomized prospective study of patients with BPPV.


METHODS
Seventy-one patients were randomized to one of three groups at their first clinic visit. These groups included the PRM, a sham PRM, and a control group. Patients were followed up in clinic at 2 weeks and 3 months. The mean long-term follow-up was 12 months. A telephone questionnaire was also conducted.


RESULTS
At 2-week follow-up, 81.8% of patients in the PRM group had a resolution of symptoms and a negative Dix-Hallpike test compared with 15.3% in the sham PRM group and 60% in the control group. This difference was statistically significant between the treatment (PRM) and sham PRM groups and between the sham and control groups. It nearly reached significance between the treatment and control groups (p = .06). The sham treatment group had by far the worst outcome at the 2-week interval. There was no statistically significant difference between the groups after 2 weeks.


CONCLUSIONS
The PRM is side specific. It may help induce remission of the vertiginous symptoms of BPPV in the short term. This cannot be attributable to a placebo effect. The PRM does not seem to affect the natural history of the disorder in the long term. The sham treatment causes a delay in spontaneous recovery, possibly by preventing the particles from falling into the utricle. This study has not compared the frequency or severity of symptoms.
Sherman
D
D
Department of Surgery, Dalhousie University, Halifax, Nova Scotia.
Massoud
E A
EA
D002137:Calculi / Q000150:complications; D004710:Endolymph; D005500:Follow-Up Studies; D006257:Head / Q000502:physiology*; D019416:Head Movements; D006801:Humans; D007759:Labyrinth Diseases / Q000150:complications; D011187:Posture; D011446:Prospective Studies; D012444:Saccule and Utricle / Q000473:pathology; D012665:Semicircular Canals; D016896:Treatment Outcome; D014717:Vertigo / Q000209:etiology / Q000628:therapy*